Page 5 - Heart Failure Guidelines
P. 5
Pediatric Heart Failure Guidelines
Medical Management for ARVC ............................................................................................33
Follow up for ARVC ...............................................................................................................33
Chemotherapy Induced Cardiomyopathy ..................................................................................34
Additional Evaluation for Patient with Chemotherapy Induced Cardiomyopathy ....................34
Medical Management Chemotherapy Induced Cardiomyopathy ............................................34
Follow-up Schedule for Chemotherapy Induced Cardiomyopathy ..........................................34
Neuromuscular Disorder Associated Cardiomyopathy ..............................................................35
Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .35
Introduction ...............................................................................................................................35
Initial Evaluation ........................................................................................................................35
Ongoing Management ...............................................................................................................35
Dose escalation plan (outpatient monitoring) .........................................................................36
Imaging .....................................................................................................................................37
Arrhythmia Screening ................................................................................................................37
Advanced Therapies .................................................................................................................37
Myocarditis ................................................................................................................................38
Additional Evaluation for possible Myocarditis .......................................................................38
Medical Management Myocarditis .........................................................................................38
Immunotherapy Management Myocarditis .............................................................................38
Follow-up Schedule for Myocarditis .......................................................................................39
Medication Doses .....................................................................................................................40
Anticoagulation Schedules ........................................................................................................42
Updated 2/11/2019 page 5